Google
ARVN Stock Price & Analysis — Arvinas Inc (Healthcare >> Biotechnology)
ARVN FAQ
What is ARVN's ROE?
Arvinas Inc reports a Return on Equity (ROE) of -57.21%.
What is ARVN's dividend yield?
Arvinas Inc offers a dividend yield of 0.00%.
What is ARVN's Quality Score?
Our AI rates ARVN's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARVN?
Our AI Timing Score for ARVN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARVN belong to?
Arvinas Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
ARVN AI Analysis Summary
Our AI summary for ARVN: Arvinas Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -57.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 8.03
Price
-0.27
(-3.25%)
Day Change
|
|
|---|
ARVN, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.03 |
| PBV / Sector |
1.38 / 5.20
GOOD
|
| Earning Per Share | -3.32 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
4.71 M
GREAT
|
| Average 1W Daily Value |
4.77 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:29 |
| Symbol | ARVN |
| Name | ARVINAS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 64.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 535.53 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5 Science Park, New Haven, CT, United States, 06511
Phone: 203 535 1456
Website: https://www.arvinas.com
Employees: 246
Sector: Healthcare >> Biotechnology
Description: Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap